Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Muparfostat

Drug Profile

Muparfostat

Alternative Names: Mannopentaose phosphate sulfate; Muparfostat sodium; Phosphomannopentaose sulfate; PI-88; PI-88 sodium; PI88-cpd; Sulfated mannopentaose phosphate

Latest Information Update: 27 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Australian National University
  • Developer Medigen Biotechnology Corporation; Progen Pharmaceuticals; Progen Pharmaceuticals Limited; TBG Diagnostics Limited
  • Class Antineoplastics; Antithrombotics; Mannans; Oligosaccharides
  • Mechanism of Action Fibroblast growth factor inhibitors; Heparanase inhibitors; Heparin cofactor II stimulants; Lipoprotein-associated coagulation inhibitor stimulants; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Liver cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Liver cancer
  • Phase I/II Solid tumours
  • Discontinued Cardiovascular disorders; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Prostate cancer; Thrombosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 09 Aug 2017 Adverse events and efficacy data from the phase III PATRON trial in Liver cancer released by Medigen Biotechnology
  • 08 Aug 2017 Adverse events data from a phase II trial in Liver cancer released by Medigen Biotechnology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top